PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc. (NASDAQ:BJCT), a leading developer of needle-free injection therapy systems, today announced that, as anticipated, on May 20, 2008, the Company received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market LLC (the “Staff Determination”) notifying the Company that, based upon the Company’s non-compliance with the $1.00 minimum bid price requirement set forth in NASDAQ Marketplace Rule 4310(c)(4), the Company’s securities are subject to delisting from The NASDAQ Capital Market unless the Company requests a hearing before the NASDAQ Listing Qualifications Panel (the “NASDAQ Panel”).
